Medpace Holdings Inc (MEDP) Position Lifted by Susquehanna International Group LLP

Susquehanna International Group LLP boosted its holdings in shares of Medpace Holdings Inc (NASDAQ:MEDP) by 30.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,947 shares of the company’s stock after buying an additional 2,347 shares during the period. Susquehanna International Group LLP’s holdings in Medpace were worth $317,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. GSA Capital Partners LLP increased its holdings in shares of Medpace by 173.8% in the third quarter. GSA Capital Partners LLP now owns 28,200 shares of the company’s stock valued at $900,000 after purchasing an additional 17,900 shares during the period. Convergence Investment Partners LLC increased its holdings in shares of Medpace by 13.4% in the third quarter. Convergence Investment Partners LLC now owns 24,819 shares of the company’s stock valued at $792,000 after purchasing an additional 2,940 shares during the period. OxFORD Asset Management LLP increased its holdings in shares of Medpace by 21.1% in the third quarter. OxFORD Asset Management LLP now owns 98,605 shares of the company’s stock valued at $3,135,000 after purchasing an additional 17,161 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Medpace by 42.8% in the third quarter. Wells Fargo & Company MN now owns 10,354 shares of the company’s stock valued at $330,000 after purchasing an additional 3,104 shares during the period. Finally, Citadel Advisors LLC increased its holdings in shares of Medpace by 219.8% in the third quarter. Citadel Advisors LLC now owns 22,133 shares of the company’s stock valued at $706,000 after purchasing an additional 15,213 shares during the period. 16.80% of the stock is currently owned by institutional investors.

A number of research analysts have recently weighed in on the company. BidaskClub raised Medpace from a “hold” rating to a “buy” rating in a report on Thursday, December 14th. Zacks Investment Research raised Medpace from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a report on Wednesday, December 13th. Jefferies Group increased their price objective on Medpace from $34.00 to $38.00 and gave the company a “hold” rating in a report on Wednesday, November 1st. William Blair lowered Medpace from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 1st. They noted that the move was a valuation call. Finally, Robert W. Baird increased their price objective on Medpace from $32.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, October 31st. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Medpace presently has a consensus rating of “Hold” and an average target price of $36.60.

In related news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of the firm’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $30.16, for a total transaction of $138,736,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 25.80% of the stock is owned by company insiders.

Shares of Medpace Holdings Inc (NASDAQ MEDP) opened at $37.65 on Tuesday. The company has a market capitalization of $1,354.42, a PE ratio of 24.52, a P/E/G ratio of 1.85 and a beta of -0.96. Medpace Holdings Inc has a 1-year low of $21.76 and a 1-year high of $39.64. The company has a current ratio of 0.68, a quick ratio of 0.68 and a debt-to-equity ratio of 0.36.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, October 30th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04. The firm had revenue of $98.68 million for the quarter, compared to analyst estimates of $96.84 million. Medpace had a return on equity of 10.00% and a net margin of 6.44%. Medpace’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period last year, the company earned $0.40 earnings per share. analysts predict that Medpace Holdings Inc will post 1.5 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2017/12/19/medpace-holdings-inc-medp-position-lifted-by-susquehanna-international-group-llp.html.

Medpace Company Profile

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply